Skip to content

GT Biopharma, Inc.

GTBP

CIK 0000109657

← back to feed
Revenue (TTM)
$0
Q1 May 2026
Net Income (TTM)
−$25.48M
−441.7% YoY Q1 May 2026
EPS Diluted (TTM)
−$10.32
−742.3% YoY Q1 May 2026
Gross Margin
—
Q1 May 2026
Operating Margin
—
Q1 May 2026
Net Margin
—
Q1 May 2026
Free Cash Flow (TTM)
−$11.74M
Q1 May 2026
Cash
$8.92M
Q1 May 2026
Total Debt
—
Q1 May 2026
Shares Outstanding
36.06M sh
Q1 May 2026

Revenue & Net Income

EPS (Diluted)

Cash Flow

Revenue Growth (YoY)

No data available for this metric.

Balance Sheet

Cash vs Debt

Recent filings